Found 1 clinical trials
A Trial of Neoadjuvant mXELOXIRI Versus CRT in the EMVI Positive LARC
Extramural Vascular Invasion Positive(EMVI+) is a high risk of distant metastasis for locally advanced rectal cancer(LARC) after resection. The study is to evaluate the efficacy and safety of XELOXIRI as neoadjuvant chemotherapy alone for EMVI+ LARC in contrast to the efficacy of standard Chemoradiotherapy (CRT).
cancer
adenocarcinoma
rectal carcinoma
renal function
chemoradiotherapy
- 0 views
- 19 Feb, 2024